Palbociclib

Overview

Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC 50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma.

Application

Products | Products > Disease Areas > Lung Adenocarcinoma | Products > Disease Areas > Luminal Breast Cancer | Products > Disease Areas > HER-2 Positive Breast Cancer | Products > Disease Areas > Triple-Negative Breast Cancer | Products > Disease Areas > Metastatic Breast Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CDK

Product Information

• Catalog No.: HY-50767
• CAS No.: 571190-30-2
• Molecular Formula: C24H29N7O2
• Molecular Weight: 447.53
• Purity: 99.90%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: ≥ 2 mg/mL (4.47 mM); Clear solution
• Availability: In-stock

Source

Original product source